TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03739970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product (Silk Peptide)
Description: * Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group - Placebo Product
Description: * Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks
Study: NCT04057443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support
Description: Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hematologic Drug
Description: The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematologic Drug
Description: The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
Study: NCT03265691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early detection and treatment of hyponatremia
Description: In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention (SOC)
Description: Usual pattern of work will be performed in all patients who enter in Hospital.
Study: NCT01752283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-assisted thyroidectomy
Description: Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted thyroidectomy
Description: Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
Study: NCT02531295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui extract powder prepared as tea
Description: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui extract powder prepared as tea
Description: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui extract powder prepared as tea
Description: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
Study: NCT05451381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: sedation after cardiac surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: sedation after cardiac surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Propofol
Description: sedation after cardiac surgery
Study: NCT02835443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Electrical stimulation of the dentate nucleus area of the cerebellum.
Study: NCT03918239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP643
Description: Participants will receive injection of SHP643.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP643
Description: Participants will receive injection of SHP643.
Study: NCT01714596

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PO versus IV antibiotics Route of administration evaluation
Description: This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PO versus IV antibiotics Route of administration evaluation
Description: This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
Study: NCT00781742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: IV once per dosing day, multiple times during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: IV once per dosing day, multiple times during the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline IV once per dosing day multiple times during the treatment period
Study: NCT00963989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra System
Description: The Penumbra System is used to revascularize clotted cerebral blood vessels.
Study: NCT01301768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Education
Description: Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
Study: NCT03069820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Patients receive TP (docetaxel and cisplatin) chemotherapy
Study: NCT01492179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline would be administered intravenously and intra-abdominally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lidocaine
Description: Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-abdominal Lidocaine
Description: Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
Study: NCT04057820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Finnegan Neonatal Abstinence Scoring Tool
Description: The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
Study: NCT01752283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted thyroidectomy
Description: video-assisted thyroidectomy under general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-assisted thyroidectomy
Description: video-assisted thyroidectomy under general anesthesia
Study: NCT02360761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Description: Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
Study: NCT02516839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC)
Description: Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
Study: NCT00135421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexacerfont
Description: Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Study: NCT02516839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWL + ROC
Description: BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education, Stress Management and Social Support
Description: Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
Study: NCT00804960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Std IVF Protocol
Description: 2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
Study: NCT02372266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Maternal-Newborn Infant Discharge
Description: Discharge from the hospital between 12-24 hours of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine discharge
Description: Discharge of the mother and newborn 2 to 3 days after delivery
Study: NCT01561703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
Study: NCT01547780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28 and Positron Emission Tomography (PET)
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28 and Positron Emission Tomography (PET)
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28 and Positron Emission Tomography (PET)
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28 and Positron Emission Tomography (PET)
Description: Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
Study: NCT00464490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
Study: NCT00247611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeWindows Intervention Sessions
Description: At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
Study: NCT01350544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Advocacy
Description: Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
Study: NCT00135421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Study: NCT02153840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSORI-CM01（YXBCM01） granule
Study: NCT03188042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rtACS Stimulation
Description: Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
Study: NCT00925938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00521300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct surgery for acromegaly
Description: Direct transsphenoidal surgery
Study: NCT02153840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSORI-CM01（YXBCM01） granule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04486560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651
Description: ERBE 1.1mm flexible single-use cryoprobe with oversheath
Study: NCT01719757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Description: Twice daily
Study: NCT01947270

Intervention type: OTHER
Intervention:  Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)
Description: The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis
Study: NCT00603590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Inactive tablet Once a day Identical in appearance to intervention drug
Study: NCT03603067

Intervention type: PROCEDURE
Intervention: Ocular surgery
Description: Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.

Intervention type: PROCEDURE
Intervention: Ocular surgery
Description: Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
Study: NCT04674943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
Study: NCT05813821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship in surgery
Description: Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team.
Study: NCT04214080

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Description: NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT)
Description: NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding and oral-motor intervention strategies
Description: Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding and oral-motor intervention strategies
Description: Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck and trunk stabilization exercises
Description: Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
Study: NCT00876031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofosfamide, idarubicin, etoposide
Description: oral maintenance therapy for 6 months
Study: NCT02057042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-assisted computerized CBT
Description: Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues